Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of patients initiating golimumab or infliximab and characteristics of their prescribing clinicians

From: Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

 Golimumab (N = 2843)Infliximab (n = 5174)SMD
Physician-specific factors
 Female sex679 (23.9%)1368 (26.4%)0.06
 Age in years, mean (STD)52.74 (9.43)51.40 (9.29)0.14
 Years in practice20.75 (10.86)18.68 (10.81)0.19
 Ownership of infusion center2528 (88.9%)4162 (80.4%)0.24
 Office-based practice**2230 (78.4%)3906 (75.5%)0.07
Type of employment
 Federal government108 (3.8%)185 (3.6%)0.01
 Group practice1298 (45.7%)2237 (43.2%)0.05
 Local government180 (6.3%)409 (7.9%)0.06
 Medical school79 (2.8%)110 (2.1%)0.04
 Other567 (19.9%)1187 (22.9%)0.07
 Solo practice611 (21.5%)1046 (20.2%)0.03
Patient-specific factors
 Demographics
  Age in years, mean (STD)70.01 (8.90)68.66 (9.47)0.15
  Female2287 (80.4%)3988 (77.1%)0.08
  White2349 (82.6%)4233 (81.8%)0.02
  Dual eligible for Medicare and Medicaid348 (12.2%)886 (17.1%)0.14
  Disability according to Medicare as original reason for Medicare eligibility1004 (35.3%)1676 (32.4%)0.06
 Comorbidity diagnoses, %
  Myocardial infarction137 (4.8%)226 (4.4%)0.02
  Coronary heart disease554 (19.5%)977 (18.9%)0.02
  Peripheral vascular disease217 (7.6%)389 (7.5%)0.00
  Chronic pulmonary disease771 (27.1%)1359 (26.3%)0.02
  Peptic ulcer disease52 (1.8%)86 (1.7%)0.01
  Diabetes658 (23.1%)1168 (22.6%)0.01
  Renal disease287 (10.1%)462 (8.9%)0.04
  Malignancy195 (6.9%)331 (6.4%)0.02
  Fibromyalgia591 (20.8%)978 (18.9%)0.05
 RA and other medications, %
  Methotrexate1642 (57.8%)3595 (69.5%)0.25
  Other conventional DMARDS1085 (38.2%)2386 (46.1%)0.16
  Oral glucocorticoids2039 (71.7%)3914 (75.6%)0.09
  NSAIDs1299 (45.7%)2453 (47.4%)0.03
  Opioid2030 (71.4%)3585 (69.3%)0.05
  Statin1315 (46.3%)2219 (42.9%)0.07
  Other lipid lowering drug257 (9.0%)418 (8.1%)0.03
  Anti-hypertensive drug2202 (77.5%)3822 (73.9%)0.08
  Anti-depressant drug use1283 (45.1%)2181 (42.2%)0.06
 Healthcare utilization
  Number of physician visits, Mean (STD)17.89 (9.35)16.96 (9.17)0.10
  Any hospitalization604 (21.2%)1027 (19.8%)0.03
  Colon cancer screening442 (15.5%)931 (18.0%)0.07
  Breast cancer screening1197 (42.1%)2097 (40.5%)0.03
  1. SMD standardized mean difference. A SMD > 0.10 (italicized) is indicative of a potentially important difference
  2. Data shown as mean (standard deviation) or n (%)
  3. *Two consecutive infusions with a dose increase, or frequency increase, were required to satisfy this definition
  4. **Rather than hospital-based practice, research, or other/missing designations